glp-1 drug market size Receptor Agonist Size, Share GLP-1 Receptor Agonist Market Size

In recent years, higher doses of some GLP-1 RAs have been used for obesity treatment, with liraglutide (3 mg) and semaglutide (2.4 mg) showing marked efficacy in inducing WL

As evidence accumulates on the broader benefits of GLP-1 therapies, pressure is building to expand reimbursement for obesity indications

Dulaglutide and lixisenatide continue to be key molecules in terms of importance for the time being, however, as the pipeline molecules can offer a wide variety of innovative formulations the competition is growing

Christian Wber: has received honoraria consultancy/speaking from Apomedica, Curelator, Eli Lilly, Grnenthal, Hermes, Lundbeck, Novartis, Pfizer, Ratiopharm/Teva, and Stada

In a study, cells were treated with 30 mM glucose with or without liraglutide (50, 100 nM) for 24 hours, after which VEGF-A and IL-6 levels were measured using ELISA

doi: 10.1111/j.1476-5381.1996.tb15466.x